FDA Issues Warning Letter for Ketamine

The FDA has issued a warning letter regarding the use of ketamine outside of FDA-approved conditions. This notice seems to be in response to the growing use of ketamine for the treatment of mental health conditions.

With the increased and un-regulated use of ketamine to treat mental health conditions (outside of ketamine’s original FDA approval) there have been growing concerns of misuse, abuse, and other potential dangers — the likely motivation behind this letter.

The FDA is generally supportive of ketamine development, so this warning shouldn’t be taken as a sign of the FDA growing sour on ketamine. For example, PharmaTher has recently received 5 different FDA orphan drug designations for its ketamine developments.

With ketamine increasing in medical and recreational use, this letter is a good opportunity to review some of the basics of ketamine in both its FDA-approved and “off-label” use. Here are some highlights from the FDA’s notice with additional context (some points taken directly from the letter):

• Ketamine is a Schedule III controlled substance FDA-approved as an intravenous or intramuscular injection for general anesthesia.

• Ketamine is not FDA approved for the treatment of psychiatric disorders. Despite it being used “off-label” for mental health conditions, the FDA has not approved ketamine as safe and effective for such uses.

• Ketamine products used by clinics and telehealth providers are “compounded” ketamine, not the FDA-approved version of the drug.

• Drug compounding is the process of combining, mixing, or altering approved ingredients to create a tailored medication. In some cases, they can serve an important role for patients whose medical needs cannot be met by an FDA-approved drug product.

• Compounded drugs, including compounded ketamine products, are not FDA-approved, which means the FDA has not evaluated their safety, effectiveness, or quality prior to marketing.

• Use of compounded ketamine products without monitoring by a health care provider for sedation (sleepiness), dissociation (disconnection between a person’s thoughts, feelings, and sense of space, time, and self), and changes in vital signs (such as blood pressure and heart rate) may put patients at risk for serious adverse events.

• Spravato (which includes only the esketamine molecule), is the only FDA-approved ketamine product for mental health conditions; a nasal spray for treatment-resistant depression in adults with major depressive disorder with acute suicidal ideation (in conjunction with an oral antidepressant).

For more on ketamine’s increased use and potential issues, check out A Deeper Look at Ketamine and its Potential for Addiction

The post FDA Issues Warning Letter for Ketamine appeared first on Microdose.

telehealth
medical
ketamine
major depressive disorder
depressive disorder
depression
antidepressant
fda